연구개발
전문가와 협업을 통해 다양한 R&D에 투자 함으로써 언제나 더 나은 미래를 모색 합니다.
전문가와 협업을 통해 다양한 R&D에 투자 함으로써 언제나 더 나은 미래를 모색 합니다.
2024
UI022, UI023(Platelet aggregation inh.)
New Combination
UI068(Antidiabetics)
New Combination
UI085(GERD)
New Combination
2025
UI093(Lipid modifying agent)
New Combination
UI009(COPD)
New Combination
UI059(GERD)
New Combination
UI086(Lipid modifying agent)
New Combination
2026
UI061(Lipid modifying agent)
New Combination
UI064(Allergic rhinitis)
New Combination
UI087, UI088(Antidiabetics)
New Combination
UI083(GERD)
New Combination
UI070, UI071(Antidiabetics)
New Combination
2027
UI089, UI090, UI091, UI092(Anti Hypertension + Lipid modifying agent)
New Combination
UI078, UI079(Lipid modifying agent)
New Combination
UI028(Functional Dyspepsia)
New Combination
2028
UI107(Functional Dyspepsia)
New Combination
UI081, UI082(Lipid modifying agent)
New Combination
UI094(GERD)
New dosage form
UI099(NSAIDs.)
New dosage form
UUI101, UI102, UI103, UI104(Anti Hypertension + Hypoglycemic agent)
New Combination
2029
UI066(Vasodilators)
New dosage form
수립예정
UI105(Anticancer)
Injection
UI060(NSAIDs)
New Combination
UI106(Asthma, COPD)
Inhaler
UI095, UI096, UI097, UI098(Anti Hypertension + Lipid Modying agent)
New Combination